



Bordetella hinzii: an Unusual Pathogen in Human Urinary Tract Infection

 Nived Collercandy,^{a,b} Camille Petillon,^a Maryam Abid,^a Charlotte Descours,^b Claudia Carvalho-Schneider,^b Laurent Mereghetti,^{a,c}
 Marie-Frederique Lartigue^{a,c}

^aCentre Hospitalier Universitaire de Tours, Service de Bactériologie, Virologie, et Hygiène Hospitalière, Tours, France

^bCentre Hospitalier Universitaire de Tours, Service de Médecine Interne et Maladies Infectieuses, Tours, France

^cUniversité de Tours, INRAE, ISP, Tours, France

KEYWORDS *Bordetella hinzii*, urinary tract infections, pyelonephritis, lithiasis

A 37-year-old man with no prior medical history except chronic alcohol and tobacco consumption was admitted for fever at 38.5°C and abdominal pain starting 2 days before admission. Physical examination confirmed tenderness of the left flank with no other abnormalities. Blood testing found increased C-reactive protein (208 mg/liter), a high white blood cell count of 15×10^9 /liter, acute renal failure with a creatinine level of 142 μ mol/liter, and a negative blood culture. Tomodensitometry revealed a urinary lithiasis of 3 cm and 800 Hounsfield units' density in the left renal pelvis associated with major homolateral hydronephrosis, which confirmed a diagnosis of left obstructive pyelonephritis. Urine was drawn by bladder catheterization before starting antibiotherapy that included ceftriaxone and amikacin. A double J catheter was installed via endoscopic intervention, and renal pelvis urine was collected.

Urine samples from both bladder and renal pelvis showed pyuria with >700 leukocytes/mm³. Nonspun pyelic urine showed Gram-negative short bacilli. Incubation for 24 h on chromogenic agar (Brilliance UTI agar, Oxoid, UK) at 37°C revealed 10^6 CFU of smooth and grayish colonies/ml. Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS; Microflex LRF, Bruker Daltonics, Germany) identified *Bordetella hinzii* with an excellent score (2.45) using the MALDI Biotyper IVD library as already reported by Fabre et al. (1). Identification was confirmed by partial sequencing of the 16S rRNA gene that showed 99% identity with *B. hinzii*. Antimicrobial susceptibility testing was performed on Mueller-Hinton plates at $35 \pm 2^\circ\text{C}$ using the Etest technique (bioMérieux, France) (Table 1).

At day 2 from admission, the patient still presented fever at 39°C, so the antibiotherapy was switched to trimethoprim-sulfamethoxazole, given the low MIC. Apyrexia was obtained at day 4. Diabetes mellitus, hypogammaglobulinemia, and HIV screening were negative. The patient was discharged from the hospital at day 7 from admission with a total antibiotic course of 14 days with a favorable outcome.

B. hinzii is a small Gram-negative rod, which can be easily identified in culture after 24 h of incubation by using MALDI-TOF MS. It is considered as a pathogen in poultry's respiratory tract infections and was also isolated in rodents, but it has rarely been described in humans (1). To our knowledge, only 11 cases of human infections have been described, in addition to our case, involving pulmonary infection, bacteremia, endocarditis, chronic cholangitis, and peripancreatic and subcutaneous abscesses (2–8). No case of urinary tract infection has ever been reported. Urinary tropism of *B. hinzii* has not been described in animal infections either. Like our patient, three other immunocompetent individuals were affected, whereas in most cases predisposing factors are identified.

Citation Collercandy N, Petillon C, Abid M, Descours C, Carvalho-Schneider C, Mereghetti L, Lartigue M-F. 2021. *Bordetella hinzii*: an unusual pathogen in human urinary tract infection. J Clin Microbiol 59:e02748-20. <https://doi.org/10.1128/JCM.02748-20>.

Editor Brad Fenwick, University of Tennessee at Knoxville

Copyright © 2021 American Society for Microbiology. All Rights Reserved.

Address correspondence to Marie-Frederique Lartigue, lartigue@univ-tours.fr.

Accepted manuscript posted online
13 January 2021

Published 19 March 2021

TABLE 1 Antimicrobial drug susceptibility testing for *B. hinzii* using the Etest technique^a

Antimicrobial drug	MIC (mg/liter)	Interpretation ^b	CASFM/EUCAST PK-PD breakpoint (mg/liter)	
			S ≤	R >
Amoxicillin	24	R	2	8
Amoxicillin/clavulanic acid	6	I	2	8
Piperacillin-tazobactam	1	S	4	16
Cefotaxime	>32	R	1	2
Ceftazidime	2	S	4	8
Imipenem	1.5	S	2	4
Meropenem	0.094	S	2	8
Gentamicin	2	S	2	4
Amikacin	8	S	8	16
Tobramycin	6	R	2	4
Ciprofloxacin	1	R	0.25	0.5
Levofloxacin	1	I	0.5	1
Trimethoprim-sulfamethoxazole	0.047	ND	ND	ND

^aND, not determined; R, resistant; S, susceptible; I, intermediate/susceptible with high dosage.

^bInterpretation based on 2019 CASFM/EUCAST recommendations (9) using PK-PD (non-species related) breakpoints.

Our patient did not report any recent avian exposure that would have led to the contagion, but he notably had been breeding hens until 2 years before. A second hypothesis could be contamination through intake of insufficiently cooked infected poultry. Since long-lasting (up to 6 months) digestive carriage of *B. hinzii* has been described, chronic colonization should also be considered (6).

B. hinzii, for which EUCAST breakpoints have not been determined, was investigated for antimicrobial susceptibility using interpretation based on pharmacokinetic/pharmacodynamic (PK-PD) breakpoints, and the patient was probably treatable with ceftazidime, piperacillin-tazobactam, carbapenems, and aminoglycosides (except tobramycin) but not amoxicillin, ceftriaxone, and fluoroquinolones. First-line antibiotics for urinary tract infection are thus inefficient. In two previous cases, *B. hinzii* persisted in patients treated with trimethoprim-sulfamethoxazole, for which no PK-PD breakpoints were available, despite a low MIC (8, 9).

In conclusion, we report the first case of *B. hinzii* in human urinary tract infection. Microbiologists and clinicians should be aware of its implication in human infections in order to improve its diagnosis and management. Whether *B. hinzii* urinary presentation was secondary to the underlying lithiasis rather than a new pathogenicity requires further clinical and microbial investigations.

ACKNOWLEDGMENTS

We thank the laboratory technicians who helped to identify this pathogen.

We have no conflicts of interest regarding the publication of this study.

REFERENCES

- Fabre A, Dupin C, Bénézit F, Goret J, Piau C, Jouneau S, Guillot S, Mégraud F, Kayal S, Desrués B, Le Coustumier A, Guiso N. 2015. Opportunistic pulmonary *Bordetella hinzii* infection after avian exposure. *Emerg Infect Dis* 21:2122–2126. <https://doi.org/10.3201/eid2112.150400>.
- Funke G, Hess T, von Graevenitz A, Vandamme P. 1996. Characteristics of *Bordetella hinzii* strains isolated from a cystic fibrosis patient over a 3-year period. *J Clin Microbiol* 34:966–969. <https://doi.org/10.1128/JCM.34.4.966-969.1996>.
- Cookson BT, Vandamme P, Carlson LC, Larson AM, Sheffield JV, Kersters K, Spach DH. 1994. Bacteremia caused by a novel *Bordetella* species, "*B. hinzii*." *J Clin Microbiol* 32:2569–2571. <https://doi.org/10.1128/JCM.32.10.2569-2571.1994>.
- Hristov AC, Auwaerter PG, Romagnoli M, Carroll KC. 2008. *Bordetella hinzii* septicemia in association with Epstein-Barr virus viremia and an Epstein-Barr virus-associated diffuse large B-cell lymphoma. *Diagn Microbiol Infect Dis* 61:484–486. <https://doi.org/10.1016/j.diagmicrobio.2008.03.013>.
- Zohourian H, Sorokin AV, Ladna JM, Mushtaq F. 2019. *Bordetella hinzii*: an unexpected pathogen in native valve endocarditis. *Can J Cardiol* 35:1604.e17–1604.e19. <https://doi.org/10.1016/j.cjca.2019.08.016>.

6. Arvand M, Feldhues R, Mieth M, Kraus T, Vandamme P. 2004. Chronic cholangitis caused by *Bordetella hinzii* in a liver transplant recipient. *J Clin Microbiol* 42:2335–2337. <https://doi.org/10.1128/jcm.42.5.2335-2337.2004>.
7. Kampmeier S, Rennebaum F, Schmidt H, Riegel A, Herrmann M, Schaumburg F. 2020. Peripancreatic abscess supported by *Bordetella hinzii*. *New Microbes New Infect* 34:100650. <https://doi.org/10.1016/j.nmni.2020.100650>.
8. Negishi T, Matsumoto T, Shinagawa J, Kasuga E, Horiuchi K, Natori T, Sugano M, Uehara T, Honda T. 2019. A case of subcutaneous abscess due to *Bordetella hinzii*. *Diagn Microbiol Infect Dis* 95:114865. <https://doi.org/10.1016/j.diagmicrobio.2019.07.003>.
9. Société Française de Microbiologie. 2019. Concentrations critiques PK/PD, non reliées à une espèce, p 31–37. *In* CASFM/EUCAST: Société Française de Microbiologie 2019. EUCAST, Basel, Switzerland.